145726
DL-Tyrosine
99%
Synonyme(s) :
(±)-2-Amino-3-(4-hydroxyphenyl)propionic acid, 3-(4-Hydroxyphenyl)-DL-alanine
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule linéaire :
4-(HO)C6H4CH2CH(NH2)COOH
Numéro CAS:
Poids moléculaire :
181.19
UNSPSC Code:
12352209
NACRES:
NA.22
PubChem Substance ID:
EC Number:
209-113-1
Beilstein/REAXYS Number:
515881
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderassay
99%
form
powder
reaction suitability
reaction type: solution phase peptide synthesis
mp
≥300 °C (lit.)
application(s)
peptide synthesis
SMILES string
NC(Cc1ccc(O)cc1)C(O)=O
InChI
1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)
InChI key
OUYCCCASQSFEME-UHFFFAOYSA-N
Classe de stockage
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
W D Phillips et al.
Experimental neurology, 270, 29-40 (2014-12-30)
Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist. The clinical disease can be difficult to treat effectively. MuSK autoantibodies affect the neuromuscular junction in several
Shannon L Maude et al.
Blood, 125(11), 1759-1767 (2015-02-04)
Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a recently described subtype of T-ALL characterized by a unique immunophenotype and genomic profile, as well as a high rate of induction failure. Frequent mutations in cytokine receptor and Janus kinase
Martin Schlumberger et al.
The New England journal of medicine, 372(7), 621-630 (2015-02-12)
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with